Progress in sequencing technologies and clinical experiments has revolutionized immunotherapy on solid and hematologic malignancies. However, the benefits of immunotherapy are limited to specific patient subsets, posing challenges for broader application. To improve its…
Continue Reading
Welcome to the January edition of Digital Health Digest on our YouTube channel! Dive into the latest and most exciting advancements in digital healthcare, from cutting-edge diagnostic tools to innovative telehealth services. In this…
Continue Reading
What You Should Know:
– 23andMe Holding Co. (Nasdaq: ME), a genetics and biopharmaceutical company, announced The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for 23ME-01473 (referred to…
Continue Reading
New adjunct specialty facilities in India’s leading health institutions are advancing precision medicine in the country through AI. The Apollo Cancer Centre (ACC) in Bengaluru has recently opened what could be the country’s first Precision…
Continue Reading
Elephas, an oncology-focused diagnostics platform, announced it secured $55 million in Series C funding, bringing its total raise to $116.5 million. Venture Investors Health Fund and the State of Wisconsin Investment Board (SWIB) led the…
Continue Reading
Penn Medicine’s iStar emerges as a game-changing AI tool, developed by Perelman School of Medicine experts. This revolutionary application, short for Inferring Super-Resolution Tissue Architecture, presents a paradigm shift in oncology diagnostics. iStar delves…
Continue Reading
GE HealthCare’s AI can accurately predict patient responses to immunotherapy, as demonstrated in collaborative studies with VUMC and UME. The models, showcasing 70-80% accuracy, may guide more personalized treatment decisions, potentially minimizing side effects…
Continue Reading
Lunit SCOPE IO, driven by AI, achieved a groundbreaking success in a phase III trial for NSCLC patients with EGFR or ALK mutations, published in the Journal of Clinical Oncology. This marks a pivotal…
Continue Reading
In the relentless global battle against cancer, generative artificial intelligence (Gen AI) has emerged as a powerful tool in oncology’s arsenal. With the capacity to analyse vast datasets, simulate complex molecular interactions, and tailor…
Continue Reading
Dr. Jose E Vidal who is currently the CEO of CytoImmune Therapeutics, a company at the forefront of a novel natural killer cell therapy for lung cancer, currently in phase 1 clinical trials joins…
Continue Reading
